How to research a compound with no human data without deceiving yourself posts 91–120

AOD-9604 is a fragment of human growth hormone and has been discussed as a potential weight-loss agent based on theoretical mechanism. The fragment hypothesis — that the fragment retains a specific property of the intact hormone — is not settled for this compound.

Marking that as an opinion rather than a finding.

Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.

I would put the burden of proof on the interesting explanation, not the dull one.

On post #103 — agreed on the reasoning, with one qualification.

Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.

The reasoning is more useful than the number, which is why I have shown it.

Picking up post #107: that is the part I would want checked first.

For any compound without a widely available reference standard, retention-time comparisons across laboratories are close to meaningless. Only a mass result travels.

Coming back to post #107, because the follow-up matters more than the original answer.

When "no data" is the complete and final answer: if there is no published human data on a compound, that is the state of knowledge. Hope is not a substitute and reasoning from theory is not a substitute. That is not a reason for shame; it is the honest epistemic position.

An observation about research a compound that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.

Adding the measurement that post #110 says would settle it.

Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.

It is worth stating the boring hypothesis before the interesting one.

That reframing is the whole thing. The facts I already had.

Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.

It is a small point and it changes the answer, which is an awkward combination.

How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.

Where the research a compound reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.

The honest summary for most of this subcategory: a plausible mechanism, animal data, and first-hand accounts. Saying so is more useful than assembling the accounts into something that reads like evidence.

Post #116 put the caveat in the right place and I want to underline it.

Where a compound has a legitimate pharmaceutical form somewhere in the world, the labelling for that form is usually the single most useful document available and is almost never consulted here.

Adding a note of thanks rather than an opinion. I did not know most of that.

Everything in post #116 holds. The case it does not cover is the one I have.

Several compounds discussed here have no published human pharmacokinetics at all. That means half-life claims in circulation were derived from an animal model or from nothing.